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Objective: The aim of this study was to construct a prognostic index that predicts risk of
relapse in women who have completed first-line treatment for ovarian cancer (OC).
Methods: A database of OC cases from 2000 to 2010 was interrogated for International
Federation of Gynecology and Obstetrics stage, grade and histological subtype of cancer,
preoperative and posttreatment CA-125 level, presence or absence of residual disease after
cytoreductive surgery and on postchemotherapy computed tomography scan, and time to
progression and death. The strongest predictors of relapse were included into an algorithm,
the Risk of Ovarian Cancer Relapse (ROVAR) score.
Results: Three hundred fifty-four cases of OC were analyzed to generate the ROVAR
score. Factors selected were preoperative serum CA-125, International Federation of
Gynecology and Obstetrics stage and grade of cancer, and presence of residual disease at
posttreatment computed tomography scan. In the validation data set, the ROVAR score had a
sensitivity and specificity of 94% and 61%, respectively. The concordance index for the
validation data set was 0.91 (95% confidence interval, 0.85-0.96). The score allows patient
stratification into low (G0.33), intermediate (0.34Y0.67), and high (90.67) probability of
relapse.
Conclusions: The ROVAR score stratifies patients according to their risk of relapse
following first-line treatment for OC. This can broadly facilitate the appropriate tailoring of
posttreatment care and support.
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Every year, 6500 women in the United Kingdom are diag-nosed with ovarian cancer (OC), which is the fifth most
common cause of cancer death in the female population.1,2
The lethality of OC is attributable to many factors, from its
often advanced stage at presentation to its high risk of relapse.
Currently, there are no reliable means of predicting an
individual’s risk of relapse after first-line treatment for OC.
This limits clinicians’ ability to provide risk-appropriate
surveillance follow-up and survivorship support. As a result,
OC patients of all International Federation of Gynecology and
Obstetrics (FIGO) stages are required to adhere to a generic but
nonYevidence-based outpatient follow-up schedule. At most
centers, this comprises 3 monthly follow-ups for 2 years,
6monthly for 2 years, andyearly thereafter for up5or 10years.3,4
Lack of ability to predict relapse also precludes the provision of
tailored survivorship support, which is consequently based
around current symptom concerns rather than evaluation of
long-term effects of treatment on, for example, cardiovascular
or bone health. This is appropriate for the majority of patients
whose survival prognosis is less than 5 years but inadequate
for those who have been cured by treatment or can expect a
long relapse-free interval. However, the ability to tailor
risk-appropriate survivorship support and follow-up care is
hampered by difficulties in reliability predicting risk of relapse
in this setting.
Although FIGO stage at diagnosis is a clinically rele-
vant means of predicting 5-year survival and thus providing
guidance in the allocation of upfront treatment,3Y5 it is an
unreliable predictor of relapse risk. To improve on FIGO stage
alone, other statistical tools (4 nomograms and 2 scores) have
added age, performance status, molecular/genetic and blood
markers, presence of comorbidities, tumor grade and histol-
ogy, residual tumor volume after surgery, the time interval
between surgery and chemotherapy, and the presence or
absence of ascites.6Y10 Although proven superior to FIGO
staging at predicting 5-year survival from OC, these algo-
rithms are again unsuitable for predicting relapse. Having
observed that the presence of residual disease and/or persis-
tent elevation in serum CA-125 on completion of postoper-
ative chemotherapy correlated with risk of early relapse in
our patients, we aimed to develop our own risk-of-relapse
prognostic algorithm using clinicopathological information
obtained before and after first-line treatment. Our purpose
was to discriminate patientswith a low risk of recurrencewho
would most benefit from long-term treatment effects as-
sessment (and less frequent follow-up surveillance) from
those for whom a symptom-focused survivorship support
package and more frequent or responsive follow-up schedule
were more appropriate.
MATERIALS AND METHODS
Patients were selected for inclusion in our study from
our preexisting OC database composed of 500 women with a
diagnosis of OC (fallopian tube, ovarian, and primary peri-
toneal cancers were all defined here as OC) and treated be-
tween 2000 and 2010 at Imperial College Healthcare NHS
Trust (United Kingdom). The database had been collected
prospectively from 2007 until 2010 and retrospectively from
2000 to 2007. Only patients who had received a combination
of surgical cytoreduction and platinum-based chemotherapy
were included in our study. Additional information from
patients listed on the database was collected from the hospital
electronic database and medical notes. Patients with missing
information, a diagnosis of borderline OC, or those who
did not undergo surgical treatment and/or chemotherapy
postsurgery were excluded from analysis.
The patient characteristics we evaluated were preoper-
ative serum CA-125 level, FIGO tumor stage evaluated as a
categorical variable (levels 1, 2, 3, and 4 corresponding to
FIGO stages I to IV), grade (1, 2, and 3 corresponding to
histopathologic grades 1 to 3), tumor histological subtype
(serous, endometrioid, mucinous, clear cell, and ‘‘others’’),
residual disease on postchemotherapy computed tomography
(CT) scan (present or absent), and residual disease after
cytoreductive surgery (‘‘nonoptimal cytoreduction’’ meaning
gross residual disease of greater than 1 cm in diameter,
‘‘optimal cytoreduction’’ when the residual disease was
less than 1 cm, and ‘‘total cytoreduction’’ when there was
no residual disease). Patients were defined as ‘‘CA-125
expressors’’ when the CA-125 at diagnosis was 200 U/mL
or greater or ‘‘nonexpressors’’ if the CA-125 level was less
than 200 U/mL at diagnosis. For each patient, the time to first
relapse after first-line chemotherapy treatment and the time
of death were recorded.
Logistic regression analyses were used to determine
which prognostic factors were the best predictors of relapse.
The full data set was split at random into a fitting data set
(n = 254) and a validation data set (n = 100). A logistic
regression model was applied to the fitting data set, and
prognostic factors were selected using forward, backward, and
stepwise selection procedures and P = 0.05 for inclusion in the
model. Random splitting of the data set into fitting and vali-
dation sets was repeated 20 times, and the variables selected in
each random partition were recorded. The final selected
prognostic model included only variables found to be statisti-
cally significant by each selection method (forward/backward/
stepwise) in amajority of the randompartitions. To confirm this
variable selection, a ‘‘best subsets’’ regression algorithm was
also applied to the full data set to confirm the selection of
covariates in the final model, and this procedure resulted in the
selection of the same4 covariates as the ‘‘bestmodel’’ (using the
Bayes information criterion). Performance of the model was
further assessed using the ‘‘leave-one-out’’ cross-validation
technique on the full data set. For final estimates of sensi-
tivity and specificity in a validation data set, a final random
partition of the data was then made, and these variables were
included in a logistic regressionmodel applied to the fitting data
set only. For comparison with the results derived from the
validation data set, the model was also applied to the full
data set and performance statistics calculated. Finally, the
Hosmer-Lemeshow test11 was used to assess goodness of fit
of the model. The logistic regression model (Table 2) was
used to generate a multifactorial Risk of Ovarian Cancer
Relapse (ROVAR) score to predict probability of relapse. In
a final exploratory analysis, we also applied a ‘‘machine
learning’’ (boosting) algorithm to a series of random parti-
tions of the data and estimated the sensitivity and specificity
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of the resulting classifications for comparison with the
logistic regression models.12
RESULTS
Of the 500 patients listed on the database, 354met study
eligibility criteria. The remaining 146 (29%) were excluded
because of the missing information. The characteristics of
these 354 patients (termed here the ‘‘ROVAR data set’’) are
summarized in Table 1. All had a diagnosis of OC, fallopian
tube, or primary peritoneal cancer. The histological subtypes
were serous, mucinous, clear cell, endometrioid adenocarci-
noma, carcinosarcoma, or ‘‘others.’’ Included into ‘‘others’’
were transitional cell tumors (Brenner and non-Brenner types),
squamous cell carcinoma, mixed epithelial tumors, sex cord
gonadal stromal tumors, undifferentiated, and unclassified.
All patients in the ROVAR data set had undergone
cytoreductive surgery aimed at removing all visible residual
TABLE 1. Patient characteristics of the study population
Characteristics of 354 Patients Treated With Surgery and Chemotherapy
Characteristics n %
Stage
IA 2 21
IB 6
IC 65
II 32 8.8
III 178 50.3
IV 71 20
Grade
1 23 6.5
2 101 28.5
3 230 65
Histological type
Serous tumors 234 63.3
Mucinous tumors 15 4.2
Endometrioid tumors 39 11
Mixed Mullerian malignant tumor 13 3.7
Clear cell tumors 33 9.3
Other* 20 8.5
Surgical outcome
Nonoptimal (Q1 cm) 123 34.8
Optimal (G1 cm) 147 41.5
Total macroscopic (no disease left) 84 23.7
CT postchemotherapy
No residual disease 170 48
Residual disease 184 52
First relapse after treatment (surgery and chemotherapy
No 101 28.5
Yes 253 71.5
CA-125 9200 U/mL at diagnosis
No 103 29.1
Yes 251 70.9
CA-125 posttreatment
935 U/mL 98 27
G35 U/mL 256 73
*Transitional cell tumors (Brenner and non-Brenner types), squamous cell carcinoma, mixed epithelial tumors, sex cord gonadal stromal
tumors, undifferentiated, and unclassified.
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disease and for correct surgical staging.Adequate nonYfertility-
sparing cytoreductive surgery consisted of peritonealwashings,
bilateral salpingo-oophorectomy, hysterectomy, multi-
ple peritoneal biopsies of all abdominal fields, at least
infracolic omentectomy, appendectomy in case of mucinous
histology, and pelvic and para-aortic lymph nodes dissec-
tion up to the renal veins. Fertility-sparing surgery in
patients with stage IA or stage IC was used only in case of
unilateral ovarian involvement and favorable histology
(ie, mucinous, serous, endometrioid, or mixed histology and
grade 1 or 2); however, this was combined with complete
surgical staging, which included a lymphadenectomy to
exclude more advanced disease.
A total of 52 (15%) from the data set had undergone
neoadjuvant chemotherapy and received chemotherapy prior
to definitive surgical cytoreduction, whereas 302 (85%) had
adjuvant chemotherapy after upfront surgery. Follow-up lasted
more than 5 years (range, 1Y120 months) for 275 patients (78%)
in the data set. The relapse rate in the full data set was 71% at
the time analysis was completed (October 31, 2013).
The final selected model included the following
4 variables: FIGO stage and grade at diagnosis, preoperative
CA-125, and residual disease at the posttreatment CT scan.
Elevated CA-125 at diagnosis and presence of measurable
residual disease after posttreatment CTwere no/yes variables.
The sensitivity and specificity of the model to predict relapse
as applied to the validation data set were 94% and 61%,
respectively, and estimated on the full data set were 93% and
65%, respectively. Area under the receiver operating charac-
teristic (ROC) curve for the validation data set was 0.91 (95%
confidence interval, 0.85Y0.96), and that for the full data setwas
0.92 (95% confidence interval, 0.88Y0.95). The area under the
ROC curve for a model including FIGO stage alone was 0.80
(95%confidence interval, 0.75Y0.85). The leave-one-out cross-
validation technique gave an adjusted estimate of prediction
error for the model of 10.7%. The positive predictive value,
which is the proportion of predicted relapses that were
true relapses, was 84% in the validation data set. The neg-
ative predictive value, which is the proportion of predicted
no-relapse patients whowere true nonrelapses, was 83% in the
validation data set. The Hosmer-Lemeshow test resulted in P =
0.4074, indicating no evidence of lack of fit of the model.11
Comparison between the observed and expected responses
suggests that the model was well calibrated. The boosting
algorithm that we applied had overall mean sensitivity of 86%
andmean specificity of 64%, and soperformed comparably, but
slightly less well than the final logistic regression model that
was used to compute the ROVAR score. This is in line with
previously reported experience of machine-learning algorithms
in this setting.
The ROVAR score derived from the final model is the
predicted probability of relapse at 5 years from completion of
combined (surgery and chemotherapy) treatment and ranges
from 0.052 to 0.992 in the full data set. Using this score, patients
can be stratified by risk of relapse using the following cutoff
values: 0 to 0.33 = low risk, between 0.34 and 0.67 = intermediate
TABLE 2. Calculating the ROVAR score
Calculation Steps ROVAR Score Calculation
A Initial score Set initial score of j2.8899
B Tumor evident on posttreatment CT scan?
Measurable disease Add 2.9581 to initial score
Nonmeasurable disease V
C Elevated CA-125 at diagnosis?
Yes Add 1.0541
No V
D FIGO stage
I V
II Add 0.8935
III Add 1.8536
IV Add 2.5540
E Tumor grade
Well differentiated (grade 1) V
Intermediately differentiated (grade 2) Add 0.3122
Poorly differentiated (grade 3) Add 1.1800
F Subtotal derived Cumulative total of steps A-E
ROVAR score = 1 / (1 + exp (jcumulative score from steps A-E))
ROVAR risk allocation
Low risk of relapse Intermediate risk of relapse High risk of relapse
0Y0.33 0.34Y0.67 Q0.68
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risk, and 0.68 or greater = high risk. The calculations to generate
this score are shown in Table 2, with examples in Figure 1.
DISCUSSION
Knowledge of a patient’s likelihood of relapse from OC
is important for the planning and implementation of follow-up
care. Until now, the most reliable predictor of a patient’s
relapse risk has been their FIGO stage at diagnosis. Although
other scores (4 nomograms and 2 scores) have improved on
the FIGO stage as predictors of 5-year survival, they mostly
considered only advanced (stage III or IV) OC and were based
around residual disease after surgery, rather than after com-
pletion of combination frontline (ie, surgery plus chemother-
apy) treatment summarized in Table 3.13Y16 For this reason,
these scores cannot be applied to predict risk of relapse.
In light of the above, we developed the ROVAR score
with the aim of designing a score that could be applicable
across all FIGO stages of OC. We showed that 4 variables
contributed most strongly to risk of relapse, and these were
(1) tumor stage at diagnosis, (2) tumor grade at diagnosis,
(3) CA-125 at diagnosis, and (4) presence of residual disease
on CT scan after chemotherapy completion. When we applied
the score in our data set to measure the risk of relapse, we
obtained an area under the ROC curve of 0.91. When
we applied the FIGO stage with the same aim and to the same
data set, the ROC curve was 0.80.The ROVAR score was
therefore a better predictor of relapse than FIGO stage alone.
The sensitivity and specificity of the ROVAR score, estimated
on the full data set, were 93% and 65%, respectively. It
includes presence of residual disease on completion of first-line
(surgery plus chemotherapy) treatment, which we found to be
one of the best predictors of relapse. Using the ROVAR score,
each patient’s risk of relapse can be stratified into low, inter-
mediate, or high risk of relapse. This can be used to provide an
estimate of risk of relapse from the end of treatment (surgery
and first-line chemotherapy) onward.
We compared the ROVAR score to other scores and
nomograms published (summarized in Table 3). Although
specific to OC, all were designed using retrospective data
to predict 5-year survival, not relapse-free survival. Most
considered only advanced (stage II or IV) OC and were based
around residual disease after surgery, without including the
presence or absence of disease after chemotherapy treatment
Our database was representative, we compared patient
characteristics with those described in other published data
and found them to be similar.17,18 Furthermore, more than
70% of our data set had advanced stage (III or IV) OC
consistent with recent statistics.19 In our population, FIGO
stage and histological grade were 2 variables significantly
associated with risk of relapse. We did not find histological
subtype to be an independent prognostic factor. This
contradicts published studies showing that clear cell tumor
has a poorer prognosis than same-stage serous tumor.20
Perhaps the histological subtype of OC was not a statistically
significant independent prognostic factor in our population
as the majority had serous histology. Only 17% of our cohort
had rarer histological subtypes, such as clear cell tumors,
carcinosarcoma, and mucinous tumors. Moreover, we showed
tumor grade had prognostic significance, whereas other
authors have reported that grade has prognostic significance
only for serous tumors (between high- and low-grade
disease), but is not of prognostic significance for mucinous,
endometrioid, and clear cell tumors.21 This may also be
explained by the low percentage of cases in our data set with
a diagnosis of nonserous OC.
We found a strong association between CA-125 at
diagnosis and risk of relapse, and this was confirmed by
logistic regression. Our findings are in accordance with
several epidemiologic studies on the association between CA-
125 at diagnosis and survival from OC.22,23 In a recent
multinational collaborative study involving 940 patients, the
authors concluded that, especially in the context of serous OC,
the higher the CA-125 at diagnosis, the greater the likelihood
of the biomarker being independently associated with
impaired disease-free and overall survival.24 We used a
similar strategy and defined only those with CA-125 marker
levels of greater than 200 U/mL as being true CA-125
‘‘expressors’’ in view of the high number of serous OC
patients included in our analysis. Interestingly, in our cohort,
the level of CA-125 after chemotherapy treatment was less
significantly associated with risk of relapse. This contradicts
3 small retrospective studies, which reported strong associ-
ation between the CA-125 level postchemotherapy and pre-
diction of progression-free survival and overall survival.25,26
In our model, we analyzed the residual disease defined
on completion of cytoreductive surgery as well as that
observed radiologically at treatment completion. We found
that the presence or absence of measurable disease seen on CT
scan after treatment completion had greater prognostic
significance than the amount of measurable disease present
on completion of surgery. This result appears reasonable,
particularly in advanced stages because, in patients with
inoperable extraperitoneal disease, radiological remission can
be obtained only after chemotherapy, and the majority of
FIGURE 1. Examples of the ROVAR score.
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patients within our cohort had advanced disease. We did not
include age or comorbidities in our score as these can be
limiting factors to optimal surgery and chemotherapy,
themselves significant independent prognostic factors when
compared with age and comorbidities.27,28 We also did not
include pretreatment or posttreatment performance status as it
was not longitudinally documented in the patients’ records
during their treatment and has been shown to be unreliable
when objectively assessed.29
A limitation of our study is that, although accurate
for the majority of patients, the ROVAR score has relatively
low specificity, with a prediction error of 10.7%. Thus, a
healthcare professional using this score has a 10% chance
of incorrectly reassuring a patient that her risk of relapse is
low or falsely concerning her by informing her that her risk
of relapse is high. This is an important consideration when
designing an intervention around risk of relapse. Another po-
tential limitation is that patient treatment during 2000Y2010
may have differed to our current standard of care. Generally,
however, now as then, standard treatment for primary OC was
a combination of surgical cytoreduction and platinum-based
chemotherapy. Another limitation is that approximately 30%
of our population was excluded from analysis because of
missing data.
In summary, the ROVAR score is a four-variable
algorithm designed to predict risk of relapse after first-line
treatment for OC. Of the 4 variables, FIGO stage, tumor
grade, and pretreatment CA-125 level have been previously
shown to be prognostic for 5-year survival, and the fourth, the
presence of measurable disease on posttreatment CT scan, has
TABLE 3. Descriptive summary of previously published nomograms designed to predict 5-year survival in OC
Summary of Nomograms Published
Authors
Clark et al13Y16
(2001)*
Chi et al14
(2008)†
Gerestein et al15
(2009)‡
Barlin et al16
(2012)§
ROVAR
Score
FIGO stage of
OC included
I, II, III, IV IIIC stage II, III, IV I, II, III, IV All stages
Histological types of
OC included
OC OC OC OC OC
Method Retrospective Retrospective Retrospective Retrospective Retrospective
No. patients 1189 424 118 478 354
Prognostic factors included
Age ( ( Not included ( Not included
FIGO stage ( Not included Not included ( (
Histological grade ( ( Not included Not included (
Debulking surgery ( ( ( ( Not included
Preoperative albumin level ( Not included Not included ( Not included
Histological subtype ( ( Not included ( (
Hereditary breast cancer
and OC
Not included Not included Not included ( Not included
Performance status ( Not included Not included ( Not included
Preoperative platelet count Not included ( ( Not included Not included
Presence of ascites ( ( Not included Not included Not included
Alkaline phosphatase ( Not included Not included Not included Not included
Preoperative
haemoglobin
Not included Not included ( Not included Not included
Measurable disease on
posttreatment CT scan
Not included Not included Not included Not included Not included
Survival at 5 y ( ( ( ( Not included
Survival at 2 y ( Not calculated Not calculated Not calculated Not included
Risk of relapse Not calculated Not calculated Not calculated Not calculated (
Concordance index
(ROC curve) at 5 y
0.786 0.67 0.63 0.714 0.91
*Serous, endometrioid, mucinous, clear cell. mixed mesodermal, adenocarcinoma, undifferentiated.
†Serous, endometrioid clear cell, mixed.
‡Serous, mucinous, undifferentiated, miscellaneous.
§Serous, endometrioid, clear cell, mixed.
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never before been included within a prognostic score. The
ROVAR score will require careful prospective validation in a
large sample of OC patients before it is fully implemented.
However, by allowing the stratification of patients into low,
intermediate, or high risk of relapse once they have completed
first-line treatment, the ROVAR score is a useful tool
for allocating tailored, risk-appropriate survivorship and
follow-up support for patients with OC.
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